Journal article
Are the cardiovascular side effects of bevacizumab caused by autonomic nervous system toxicity?
Abstract
429
Background: Bevacizumab, a monoclonal antibody that inhibits the activity of vascular endothelial growth factor, has demonstrated activity against several malignancies. Reported adverse effects include hypertension, endothelial dysfunction, and heart failure. Animal models have suggested ANS toxicity as the mechanism. This pilot study investigates the effects of bevacizumab on short and long-term ANS function using a …
Authors
Oqab Z; McIntyre W; Hammad N; Biagi JJ; Seaborn G; Hopman W; Pal R; Simpson C; Baranchuk A
Journal
Journal of Clinical Oncology, Vol. 32, No. 3_suppl, pp. 429–429
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2014
DOI
10.1200/jco.2014.32.3_suppl.429
ISSN
0732-183X